Business context and reporting period
Insmed Incorporated (Nasdaq: INSM) filed this Form 8-K on October 5, 2026, reporting an executive change and referencing third-quarter 2026 guidance information. The filing does not provide quarterly financial results.
Key financial metrics
The 8-K text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metric values.
Material changes
- Chief Financial Officer Sara Bonstein will separate from the company effective October 30, 2026.
- Insmed said a search for her successor is underway.
- The company stated that the separation is not related to a disagreement concerning accounting practices, financial statements, internal controls, or operations.
- Ms. Bonstein will receive benefits under Section 6.e of her amended and restated employment agreement dated April 1, 2022; the filing does not specify their value.
Guidance, outlook, and risks
The filing says an October 5 press release provided certain third-quarter 2026 guidance information, but that guidance is not included in the supplied filing text. No other outlook or contingencies are detailed here.
Facts investors should verify
- Review Exhibit 99.1 for the actual third-quarter 2026 guidance and any related assumptions.
- Monitor announcements regarding the CFO successor and any further details about the transition.
- Consult the employment agreement or subsequent disclosures for the nature and amount of separation benefits.